Venture Debt in Biotech & Pharma: A 2025 Deep Dive Introduction: The Rise of Biotech Venture Debt Venture debt has emerged as a critical financing tool for biotech and pharmaceutical startups, providing non-dilutive capital to extend runway and reach key R&D milestones. Unlike traditional bank loans, venture

Executive Summary In the pharmaceutical industry, royalties serve as a fundamental mechanism for sharing value from intellectual property and products. A royalty typically grants the IP owner a percentage of sales or profits in exchange for allowing another party to use, manufacture, or sell a drug or technology. This comprehensive

Eli Lilly’s latest act of corporate altruism arrived in September 2025 in the form of TuneLab, an artificial intelligence platform dressed up as an equaliser for the drug-discovery industry. The firm claims to have spent more than $1 billion curating preclinical, safety and pharmacological data across hundreds of

Pharmaceutical & Biotech Transactions: September 8-14, 2025 Executive Summary The week of September 8-14, 2025 witnessed 22 verified transactions in the pharmaceutical and biotech sectors, with disclosed values exceeding $3.9 billion. Despite being immediately after Labor Day, the period marked significant activity in AI-enabled drug discovery

Fractional equity funding for biotech companies - achieved through traditional securities divided into smaller units rather than cryptocurrency - has evolved from experimental concept to legitimate funding mechanism, with over $1.3 billion raised through U.S. equity crowdfunding alone since 2016. The model enables retail investors to purchase biotech equity for

Absci Corporation (NASDAQ: ABSI) stands at a pivotal crossroads in September 2025, having transitioned from a pure AI drug discovery platform to a clinical-stage biopharmaceutical company. While achieving the significant milestone of advancing its first AI-designed antibody into human trials, the company confronts mounting competitive pressures, financial deterioration,

Executive Summary Neo Kuma Ventures, established in December 2020 as Europe's first venture fund dedicated to psychedelic healthcare, has deployed roughly £20 million across 15 portfolio companies according to Tech.eu reporting. The London-based fund—founded by Clara Burtenshaw, Sean McLintock, and Nick David—reported early paper

The radiopharmaceutical industry has erupted into an all-out patent war in 2024-2025, with Novartis at the center of a multi-billion dollar defensive campaign to protect its revolutionary cancer treatments. What started as a niche market for radioactive medicines has transformed into one of the pharmaceutical industry'

The Nuclear Medicine Revolution In the corridors of global pharma, an unprecedented arms race is underway. The coveted weapons aren't traditional drugs or antibodies, but radioactive atoms hitched to drug molecules – radiopharmaceuticals delivered with sniper-like precision to tumors. Once relegated to the fringes of nuclear medicine, this

The biopharma royalty financing market has emerged as a critical pillar of life sciences funding, with annual transaction volume reaching $14 billion at a 45% compound annual growth rate through 2025 according to Ernst & Young's 2025 Biotech Beyond Borders Report. This explosive growth reflects fundamental shifts in